Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects. Issue 1 (January 2017)

• Record Type: Journal Article
• Authors: Takagaki, Yuta; Koya, Daisuke; Kanasaki, Keizo
• Is Part Of: Current opinion in nephrology and hypertension. Volume 26:Issue 1(2017:Jan.)
• Page Start: 56
• Page End: 66
• Publication Date: 2017-01
• Subjects: EndMT -- fibrosis -- integrin -- microRNA -- TGF-β; Hypertension -- Periodicals; Nephrology -- Periodicals; Hypertension -- Indexes; Hypertension -- Periodicals; Kidney Diseases -- Indexes; Kidney Diseases -- Periodicals; Nephrology -- Periodicals; 616.132
• DOI: 10.1097/MNH.0000000000000291
• Languages: English
• ISSNs: 1062-4821

Abstract

Abstract : Purpose of review: This article analyzes the potential beneficial effects of dipeptidyl peptidase (DPP)-4 inhibitors on renal diseases. Recent findings: The pathological significance of DPP-4, either dependent or independent on catalytic activities, on renal diseases has been reported in preclinical studies. With regard to this, we have shown that damaged endothelial cells are converted to a mesenchymal cell phenotype, which is associated with the induction of DPP-4 in endothelial cells. The endothelial mesenchymal transition may contribute to kidney fibrosis; indeed, the antifibrotic effects of DPP-4 inhibitors have been reported elsewhere. However, even though such potential benefits of DPP-4 inhibitors on renal diseases were shown in preclinical studies, clinical trials have not yet revealed significant benefits in renal hard outcomes of DPP-4 inhibitors. Summary: To completely understand the beneficial effects of DPP-4 inhibitors, both the following studies are required: first, preclinical studies that analyze deeper molecular mechanisms of DPP-4 inhibition, and, second, clinical studies that investigate whether such potential beneficial effects of DPP-4 inhibitors are relevant to the patients in the clinic.